Furthermore, activity of EGFR inhibitors in NSCLC cells is correlated with the ability of the drugs to reduce AKT and ERK1/2 activation, and single-agent EGFR inhibition resulted in de-phosphorylation of these proteins in our HCC78-TR cells (Figures 5B and S6) [37]. Here, MAPK3 is linked to non-small cell lung carcinoma.